SCHEMBL12409282

SCHEMBL12409282

Cc1ccc(CNc2nccn3c(-c4ccc(O)cc4)cnc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 13/20 0.55
GAA P10253 4/20 0.45
MAPT P10636 4/20 0.45
TP53 P04637 2/20 0.45
THRB P10828 2/20 0.45
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
CASP1 P29466 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
PLEC Q15149 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409289 0.90 TTK (0.56) TTKADORA3
SCHEMBL12409259 0.89 TTK (0.55) TTKMAPTKDM4EMEN1ALDH1A1
SCHEMBL12409243 0.88 TTK (0.57) TTKADORA3
SCHEMBL12409244 0.88 TTK (0.68) TTKGAATP53KDM4EALDH1A1
SCHEMBL12409305 0.88 TTK (0.55) TTKADORA3
SCHEMBL12409255 0.88 TTK (0.52) TTKGAAMAPTTHRBADORA3
SCHEMBL14668729 0.88 TTK (0.53) TTKGAAMAPTTP53ADORA3
SCHEMBL12409264 0.87 ADORA3 (0.56) TTKMAPTKDM4EMEN1ALDH1A1
SCHEMBL12409256 0.86 TTK (0.53) TTK
SCHEMBL12409283 0.86 TTK (0.55) TTKGAAMAPTTP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2567960-A2 Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis Biofocus DPI Limited (GB) 2013-03-13 EP disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 TTK 3239/4885GAA 1782/4885MAPT 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.